HUTCHMED將癌症療法授權給GSK，總額最高達12.95億美元，股價跳漲15%（HCM:NASDAQ）
· seekingalpha.com
HUTCHMED與GSK簽訂KRAS/EGFR癌症療法HMPL-A830的獨家授權協議，交易總額最高可達12.95億美元。
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...